Harvard Bioscience, Inc. (HBIO)
HBIO Stock Price Chart
Explore Harvard Bioscience, Inc. interactive price chart. Choose custom timeframes to analyze HBIO price movements and trends.
HBIO Company Profile
Discover essential business fundamentals and corporate details for Harvard Bioscience, Inc. (HBIO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Instruments & Supplies
IPO Date
19 Mar 2001
Employees
331.00
CEO
John D. Duke
Description
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
HBIO Financial Timeline
Browse a chronological timeline of Harvard Bioscience, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.21, while revenue estimate is $21.45m.
Earnings released on 12 May 2026
EPS came in at -$0.33 surpassing the estimated -$0.62 by +46.77%, while revenue for the quarter reached $20.76m , missing expectations by -2.10%.
Stock split effective on 16 Mar 2026
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Mar 2026
EPS came in at -$0.01 falling short of the estimated $0.35 by -102.86%, while revenue for the quarter reached $23.74m , beating expectations by +2.75%.
Earnings released on 6 Nov 2025
EPS came in at -$0.01 falling short of the estimated $0.01 by -300.00%, while revenue for the quarter reached $20.59m , missing expectations by -10.86%.
Earnings released on 11 Aug 2025
EPS came in at -$0.01 surpassing the estimated -$0.03 by +60.00%, while revenue for the quarter reached $20.45m , beating expectations by +7.63%.
Earnings released on 12 May 2025
EPS came in at -$0.01 surpassing the estimated -$0.04 by +75.00%, while revenue for the quarter reached $21.77m , beating expectations by +1.75%.
Earnings released on 12 Mar 2025
EPS came in at $0.06 surpassing the estimated $0.05 by +20.00%, while revenue for the quarter reached $24.56m , beating expectations by +17.21%.
Earnings released on 7 Nov 2024
EPS came in at -$0.02 falling short of the estimated -$0.01 by -173.97%, while revenue for the quarter reached $21.97m , missing expectations by -9.03%.
Earnings released on 8 Aug 2024
EPS came in at -$0.03 falling short of the estimated $0.05 by -160.00%, while revenue for the quarter reached $23.10m , missing expectations by -12.51%.
Earnings released on 7 May 2024
EPS came in at $0.02 falling short of the estimated $0.02 by -14.27%, while revenue for the quarter reached $24.51m , missing expectations by -4.96%.
Earnings released on 7 Mar 2024
EPS came in at $0.04 falling short of the estimated $0.05 by -20.00%, while revenue for the quarter reached $28.15m , missing expectations by -3.29%.
Earnings released on 7 Nov 2023
EPS came in at $0.01 falling short of the estimated $0.04 by -75.00%, while revenue for the quarter reached $25.36m , missing expectations by -13.73%.
Earnings released on 8 Aug 2023
EPS came in at $0.04 falling short of the estimated $0.06 by -33.33%, while revenue for the quarter reached $28.76m , missing expectations by -3.01%.
Earnings released on 25 Apr 2023
EPS came in at $0.06 surpassing the estimated $0.05 by +20.00%, while revenue for the quarter reached $29.98m , beating expectations by +1.10%.
Earnings released on 9 Mar 2023
EPS came in at $0.04 surpassing the estimated $0.03 by +20.01%, while revenue for the quarter reached $28.43m , missing expectations by -6.27%.
Earnings released on 8 Nov 2022
EPS came in at -$0.01 falling short of the estimated $0.07 by -115.00%, while revenue for the quarter reached $26.92m , missing expectations by -6.74%.
Earnings released on 3 Aug 2022
EPS came in at $0.05 falling short of the estimated $0.06 by -16.67%, while revenue for the quarter reached $29.21m , missing expectations by -4.19%.
Earnings released on 4 May 2022
EPS came in at $0.04 falling short of the estimated $0.05 by -25.00%, while revenue for the quarter reached $28.78m , beating expectations by +0.03%.
Earnings released on 8 Mar 2022
EPS came in at $0.08 falling short of the estimated $0.10 by -20.00%, while revenue for the quarter reached $33.06m , beating expectations by +0.28%.
Earnings released on 3 Nov 2021
EPS came in at $0.06 matching the estimated $0.06, while revenue for the quarter reached $29.66m , beating expectations by +6.28%.
Earnings released on 5 Aug 2021
EPS came in at $0.06 surpassing the estimated $0.05 by +20.00%, while revenue for the quarter reached $29.20m , beating expectations by +3.76%.
HBIO Stock Performance
Access detailed HBIO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
